KEY DETAILS
Lilly CEO Dave Ricks says about 700,000 seniors have started a GLP-1 since Medicare's $50 Bridge program began July 1, and about 70% of them are on Lilly drugs.
Lilly broke ground on a $6.5 billion Houston plant to make more of its Foundayo obesity pill, which now has one-third of new GLP-1 pill patients.
Novo Nordisk plans to launch more than five blockbuster drugs by 2030, led by new obesity drugs such as CagriSema.
Novo Nordisk faces investor pressure to grow beyond its weight-loss drug business.
Analysts are debating whether Novo Nordisk's stock is undervalued or facing a real slowdown as semaglutide nears its patent cliff.
Eli Lilly CEO Dave Ricks told CNBC that about 700,000 seniors have started a GLP-1 since Medicare's $50 Bridge program began on July 1, and that about 70% of them are on Lilly drugs. Lilly is also expanding manufacturing for its Foundayo pill, and Novo Nordisk laid out a plan for new drug launches through 2030. Both companies are shaping how far this treatment category can grow, even as analysts debate what Novo's stock is worth today.
Medicare coverage for obesity drugs already exists. The GLP-1 Bridge program began on July 1 with a $50 monthly copay for eligible Part D members. Ricks said about 700,000 seniors have started a GLP-1 through it so far, and about 70% of them are taking Lilly medicines. He called the rollout very encouraging. Those numbers show how quickly access has grown since the program began, and which company is gaining more of the new patients.
Lilly is also building for more demand. Foundayo, approved and launched in April, had $98 million in second-quarter sales and now has one-third of new GLP-1 pill patients, and Lilly broke ground on a $6.5 billion Houston plant, due to run by 2030, to make more. Building capacity early can help avoid the kind of supply shortages that have affected injectable GLP-1 drugs since demand outpaced production. For patients who prefer a pill over an injection, this expansion could mean steadier supply as Foundayo reaches more patients.
Across the industry, Novo Nordisk is making its own bet on the future, and it looks different from Lilly's approach. The company aims to launch more than five blockbuster drugs by 2030, led by new obesity drugs such as CagriSema, but its shares fell as much as 9% as analysts questioned the plan. New launches would reduce Novo's reliance on Wegovy and Ozempic, two products that have driven most of its recent growth. It also reflects a longer view, since no single drug category stays dominant forever, and a broader pipeline gives Novo more ways to compete as the field gets more crowded.
That kind of diversification is not just strategic, it is something investors are actively demanding. Novo Nordisk faces pressure from shareholders who want to see growth beyond its weight-loss drug business, particularly as competitors close the gap and pricing pressure builds across the category. Investors have grown used to Novo's rapid growth over the past few years, and they are now asking what comes next once that growth slows. The pipeline expansion Novo has outlined is, in part, a direct response to that pressure.
That pressure has spilled into a broader debate among analysts about what Novo's stock is actually worth right now. Some argue the stock looks undervalued given the company's pipeline and market position, while others see a real reset underway as competition intensifies and the easy growth of the past few years fades. The disagreement comes down to how much weight to put on Novo's past performance versus the uncertainty ahead. For investors and patients alike, the outcome of that debate will shape how much capital Novo has to invest in the new drugs it says it wants to bring to market.
None of this changes what a patient should do today, but it does show where the category is heading, toward wider insurance access and tighter competition. If you currently rely on GLP-1 treatment, and you are on Medicare, it may help to check whether you qualify for the $50 Bridge program, which runs through 2027. It also makes sense to watch how Novo's expanded pipeline takes shape, since a broader lineup could change pricing and availability well beyond weight-loss drugs. Two decisions, still unfolding, are worth following closely rather than acting on right now.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.